Latest Hotspot

ACR 2023: Amgen unveils fresh results from second phase study of dazodalibep for Sjögren's disorder

15 November 2023
3 min read

Amgen has revealed fresh information from the Phase 2 trial of dazodalibep, an experimental drug aimed to treat Sjögren's. The findings will be showcased in discussions at the American College of Rheumatology Convergence 2023 taking place from November 10-15 in San Diego. The study's results indicate that dazodalibep could potentially lessen both the systemic and symptomatic disease impacts for two separate patient groups.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成The clinical development of dazodalibep, a CD40 ligand antagonist, underwent Phase 2 of its research. It was trialed in a double-blind, placebo-controlled, randomized crossover investigation, evaluating two demographic groups of Sjögren's syndrome: individuals with moderate to extreme systemic activity and those expressing equivalent symptom severity, despite not having extra organ engagement.

By May 2023, updates provided at the 2023 EULAR Congress stated that as of Day 169, dazodalibep treatment was successful in reaching the primary goal of the study in both patient clusters. The switch reports, as highlighted in the ACR presentations, showed that by Day 169, patients who initially received dazodalibep were given placebo treatment, and those who started with placebo were switched to dazodalibep. Patients were monitored for safety reasons for an additional 3 months post last dose administration.

According to Dr. David M. Reese, executive vice president of Research and Development at Amgen, there haven't been any FDA-approved treatments for Sjögren's syndrome designed to adjust the progression of the disease so far. However, the promising results of the Phase 2 trial of dazodalibep indicate that it may tackle root of the problem by minimizing systemic disease activity and alleviating severe symptoms such as fatigue and dryness.

Dazodalibep operates as a CD40 ligand antagonist, hindering the association between T cells and CD40-displaying B cells, thereby preventing the overstimulation of the CD40 ligand co-stimulatory pathway. This pathway's overactivity is linked to various autoimmune diseases. Amgen has announced that further exploration of dazodalibep will also take place in relation to focal segmental glomerulosclerosis, a rare kidney condition marked by glomeruli scarring.

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of November 14, 2023, there are 40 investigational drugs for the CD40L target, including 60 indications, 66 R&D institutions involved, with related clinical trials reaching 92, and as many as 16030 patents.

Dazodalibep shows promise as a potential treatment for a wide range of diseases across various therapeutic areas.The discontinuation of its development in China suggests that there may be specific challenges or regulatory issues in that market. Further research and development, as well as regulatory approvals, will be necessary to determine the drug's ultimate success and availability to patients.

图形用户界面, 文本, 应用程序

描述已自动生成

What are BRAF inhibitors and how do you quickly get the latest development progress?
What are BRAF inhibitors and how do you quickly get the latest development progress?
15 November 2023
BRAF mutation is one of the significant therapeutic targets for various solid tumors, with BRAF inhibitors representing a major form of targeted combination therapy for BRAF mutation-positive solid tumors.
Read →
[177Lu]Lu-PSMA-617: Brief Review of its R&D progress and the clinical outcome in 2023 ESMO
ESMO 2023
4 min read
[177Lu]Lu-PSMA-617: Brief Review of its R&D progress and the clinical outcome in 2023 ESMO
15 November 2023
[177Lu]Lu-PSMA-617 extends survival in mCRPC patients previously treated with ARPI, but its impact without prior taxane treatment was unclear until revealed at the ESCO Congress.
Read →
FluoGuide reports positive initial results from FG001 Phase IIa head and neck cancer study at International Academy of Oral Oncology meeting
Latest Hotspot
3 min read
FluoGuide reports positive initial results from FG001 Phase IIa head and neck cancer study at International Academy of Oral Oncology meeting
15 November 2023
FluoGuide A/S, a precision oncology surgery leader, shared initial results from the phase IIa trial of its leading product, FG001, for head and neck cancer surgeries, at the International Academy of Oral Oncology 2023 conference in South Korea. The study validated the product's efficacy and safety.
Read →
What are β-lactamase inhibitor and how do you quickly get the latest development progress?
What are β-lactamase inhibitor and how do you quickly get the latest development progress?
14 November 2023
β-Inhibitors can inhibit the activity of β-lactamase inhibitors produced by drug-resistant bacteria. They are typically used in combination with β-lactam antibiotics to protect the β-lactam antibiotics from hydrolysis, thereby inhibiting enzyme-resistant bacteria.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.